CDKN1B

From Wikipedia, the free encyclopedia

It has been suggested that this article or section be merged with P27 (gene). (Discuss)

Cyclin-dependent kinase inhibitor 1B (p27, Kip1)

PDB rendering based on 1jsu.

Available structures: 1jsu

Identifiers

Symbol(s)

CDKN1B; CDKN4; KIP1; P27KIP1

External IDs

OMIM: 600778 MGI: 104565 HomoloGene: 2999

Gene ontology
Molecular Function:	• cyclin-dependent protein kinase inhibitor activity • transforming growth factor beta receptor, cytoplasmic mediator activity • protein binding
Cellular Component:	• nucleus • cytoplasm
Biological Process:	• cell cycle • cell cycle arrest • sensory perception of sound • positive regulation of cell proliferation • positive regulation of microtubule polymerization • negative regulation of cyclin-dependent protein kinase activity • inner ear development • negative regulation of epithelial cell proliferation • negative regulation of cell motility

RNA expression pattern

More reference expression data

Orthologs

Human

Mouse

Refseq

NM_004064 (mRNA)
NP_004055 (protein)

NM_009875 (mRNA)
NP_034005 (protein)

Location

Chr 12: 12.76 - 12.77 Mb

Chr 6: 134.89 - 134.89 Mb

Pubmed search

[1]

[2]

Cyclin-dependent kinase inhibitor 1B (p27, Kip1), also known as CDKN1B, is a human gene.

This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state.^[1]

[edit] References

^ Entrez Gene: CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1).

[edit] Further reading

Marone M, Bonanno G, Rutella S, et al. (2003). "Survival and cell cycle control in early hematopoiesis: role of bcl-2, and the cyclin dependent kinase inhibitors P27 and P21.". Leuk. Lymphoma 43 (1): 51–7. PMID 11908736.
Hirabayashi H (2003). "[P27 expression and survival in NSCLC]". Nippon Rinsho 60 Suppl 5: 263–6. PMID 12101669.
Bloom J, Pagano M (2003). "Deregulated degradation of the cdk inhibitor p27 and malignant transformation.". Semin. Cancer Biol. 13 (1): 41–7. PMID 12507555.
Tokumoto M, Tsuruya K, Fukuda K, et al. (2003). "Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27.". Nephrol. Dial. Transplant. 18 Suppl 3: iii9–12. PMID 12771291.
Drexler HC (2004). "The role of p27Kip1 in proteasome inhibitor induced apoptosis.". Cell Cycle 2 (5): 438–41. PMID 12963837.
Le XF, Pruefer F, Bast RC (2006). "HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.". Cell Cycle 4 (1): 87–95. PMID 15611642.
Belletti B, Nicoloso MS, Schiappacassi M, et al. (2005). "p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs.". Curr. Med. Chem. 12 (14): 1589–605. PMID 16022660.